Cidfusituzumab: Difference between revisions
m Protected "Cidfusituzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 26: | Line 26: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WS}} | {{WS}} |
Latest revision as of 23:53, 8 August 2012
WikiDoc Resources for Cidfusituzumab |
Articles |
---|
Most recent articles on Cidfusituzumab Most cited articles on Cidfusituzumab |
Media |
Powerpoint slides on Cidfusituzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cidfusituzumab at Clinical Trials.gov Trial results on Cidfusituzumab Clinical Trials on Cidfusituzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cidfusituzumab NICE Guidance on Cidfusituzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cidfusituzumab Discussion groups on Cidfusituzumab Patient Handouts on Cidfusituzumab Directions to Hospitals Treating Cidfusituzumab Risk calculators and risk factors for Cidfusituzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Cidfusituzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Cidfusituzumab is a humanized monoclonal antibody which is used to treat cancers of the epithelial origin. It binds to interleukin-2.